Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-05-17
2003-04-08
Ford, John M. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C544S328000, C544S324000
Reexamination Certificate
active
06545008
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel pyrimidine derivatives and pharmaceutically acceptable non-toxic salts thereof which possess an excellent inhibitory activity against gastric acid secretion, a pharmaceutical composition containing the same as an active ingredient, and a process for the preparation thereof.
BACKGROUND OF THE INVENTION
For the treatment of peptic ulcer disease, various drugs such as antacid, anticholinergic agents, H2-receptor antagonist and proton pump inhibitor have been used. The advent of proton pump inhibitors has rekindled research activities in this field.
However, it has been pointed out that the irreversible mode of action by proton pump inhibitors may induce undesirable effects. Accordingly, various attempts to develop a reversible proton pump inhibitor (i.e., reversible acid pump antagonist) are being actively made. For example, European Patent Nos. 322,133 and 404,322 disclose quinazoline derivatives, European Patent No. 259,174 describes quinoline derivatives, and WO 91/18887 offers pyrimidine derivatives, as reversible proton pump inhibitors.
Further, the present inventors have also reported quinazoline derivatives in WO 94/14795 and pyrimidine derivatives in WO 96/05177 and WO 98/43968.
SUMMARY OF THE INVENTION
The present inventors have carried out further research to develop reversible acid pump antagonists with improved efficacy; and, as a result, have discovered that pyrimidine derivatives having one or more halogen groups at the 5- or 6-position of a pyrimidine nucleus or at the tetrahydroisoquinoline group of the 4-position of the pyrimidine nucleus exhibit excellent acid pump inhibition effects and inhibitory activity against gastric acid secretion.
Accordingly, it is a primary object of the present invention to provide novel pyrimidine derivatives having one or more halogen groups at the 5- or 6-position of a pyrimidine nucleus or at the tetrahydroisoquinoline group of the 4position of the pyrimidine nucleus, and pharmaceutically acceptable non-toxic salts thereof.
It is another object of the present invention to provide processes for preparing said compounds.
It is a further object of the present invention to provide pharmaceutical compositions for treating gastrointestinal diseases containing the same as an active ingredient.
REFERENCES:
patent: 3956495 (1976-05-01), Lacefield
patent: 3960861 (1976-06-01), Danilewicz et al.
patent: 3980781 (1976-09-01), Snell et al.
patent: 4000138 (1976-12-01), Snell et al.
patent: 4044136 (1977-08-01), Danilewicz et al.
patent: 5064833 (1991-11-01), Ife et al.
patent: 5075316 (1991-12-01), Hubele
patent: 5276186 (1994-01-01), Waditschatka
patent: 5525604 (1996-06-01), Lee et al.
patent: 0 230 871 (1987-08-01), None
patent: 0 337 943 (1989-10-01), None
patent: 0 376 806 (1990-08-01), None
patent: 0 388 838 (1990-09-01), None
patent: 0 560 726 (1993-09-01), None
patent: 0 640 599 (1995-03-01), None
patent: 1182584 (1970-02-01), None
patent: 91/18887 (1991-12-01), None
patent: 92/07844 (1992-05-01), None
patent: 92/18498 (1992-10-01), None
patent: 94/14795 (1994-07-01), None
patent: 95/10506 (1995-04-01), None
patent: 96/05177 (1996-02-01), None
patent: 97/42186 (1997-11-01), None
patent: 98/18784 (1998-05-01), None
patent: 98/43968 (1998-10-01), None
Chemical Abstracts, “Preparation of substituted pyrimide derivatives as analgesics and antiinflammatory agents”, vol. 122, Abstracts No. 290883s, p. 1041, col. 1, Jun. 5, 1995.
Chemical Abstracts, “Pyrimidine derivative for treatment of uncerative colitis”, vol. 120, Abstracts No. 86447g, p. 654, col. 2, Feb. 21, 1994.
Chemical Abstract, “Oral preparations containing antiallergy pyrimidine derivative”, vol. 112, Abstracts No. 87674z, p. 457, col. 1, Mar. 8, 1993.
Chemical Abstracts, “Herbicides. I. 2-(4-Nitroanilino)pyrimidines”, vol. 96, Abstracts No. 122741v, p. 697, col. 1, Apr. 12, 1982.
Chemical Abstracts, “Biosynthesis of 1-methyl-1,2,3,4-tetrahdroisoquinoline (1MeTIQ), a possible anti-Parkinsonism agent”, vol. 118, Abstracts No. 249869w, p. 347, col. 2, Jun. 21, 1993.
Chemical Abstracts, “Carbon dioxide: a reagent for the protection of nucleophilic centers and the simultaneous activation of electrophilic attack. Part II”, vol. 106, Abstracts No. 32801k, p. 526, col. 1, Feb. 2, 1987.
Chemical Abstracts, “Synthesis of dihydroisoquinolines and 1-substituted tetrahydroisoquinolines”, vol. 96, Abstracts No. 217665n, p. 726, col. 1, Jun. 21, 1982.
Chemical Abstracts, “An evaluation of the ortho effect in iso-cytosine derivatives: 2-aralkylamino- and 2-arylamino-3,4-dihydropyrimidin-4(3)-ones”, vol. 121, Abstracts No. 256215v, p. 1218, col. 2, Nov. 21, 1994.
Chemical Abstracts, “interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins”, vol. 114, Abstracts No. 185899p, p. 833, col. 1, May 13, 1991.
Chemical Abstracts, “Alkylation of isoquinoline skeleton in the 1-position. Lithiated 2-pivalolyl- and 2-bis(dimethylamino) phosphinolyl-1,2,3,4-tetrahydroisoquinolines”, vol. 99, Abstracts No. 158207b, pp. 597-598, col. 2, Nov. 7, 1983.
Kye Han, et al, “Pharmacokinetics of a New Reversible Proton Pump Inhibitor, YH1885, after Intravenous and Oral Administrations to Rats and Dogs: Hepatic First-pass Effect in Rats”, Biopharmaceutics & Drug Disposition, 19(8), pp. 493-500, 1988.
Byung-Nak Ahn et al, “Pharmacokinetic Study of YH1885 (I): Absorption, Distribution and Excretion of14C-YH1885 in Rats”, Yakhak Hoeji, vol. 41, No. 3, pp. 335-344, 1997.
Kye Han, et al, “Blood Partition Binding of a New Reversible Proton Pump Inhibitor, YH1885”, Biopharmaceutics & Drug Disposition, 19(6), pp. 413-415, 1998.
Hyeyoung Kim et al, “Inhibitory Effects of Reversible Proton Pump Inhibitors YH 1238 and YH1885 on Acid Secretion in Isolated Gastric Cells”, Korean J. Physiol. Pharmacol., 1(3), pages 337-343, 1997.
Kye Soo Han, et al, “Determination of a new proton pump inhibitor, YH1885, in human plasma and urine by high-performance liquid chromatography”, Journal of Chromatography B, 696(2), pp. 312-316, 1997.
Kim Chang Seop
Lee Bong Yong
Lee Jong Wook
Lee Seung Kyu
Lee Song Jin
Burns Doane , Swecker, Mathis LLP
Ford John M.
Yuhan Corporation
LandOfFree
Pyrimidine derivatives and processes for the preparation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivatives and processes for the preparation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivatives and processes for the preparation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3042081